Cargando…

Patient Treatment Preferences for Heart Failure Medications: A Mixed Methods Study

INTRODUCTION: Consideration of patient preferences for guideline-directed medical therapies (GDMT) for heart failure with reduced ejection fraction (HFrEF) may help improve major gaps in prescribing and adherence. This study aimed to identify the range and relative priority of factors influencing pa...

Descripción completa

Detalles Bibliográficos
Autores principales: Trinkley, Katy E, Kahn, Michael G, Allen, Larry A, Haugen, Heather, Kroehl, Miranda E, Lin, Chen-Tan, Malone, Daniel C, Matlock, Daniel D
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7667168/
https://www.ncbi.nlm.nih.gov/pubmed/33204073
http://dx.doi.org/10.2147/PPA.S276328
_version_ 1783610251277238272
author Trinkley, Katy E
Kahn, Michael G
Allen, Larry A
Haugen, Heather
Kroehl, Miranda E
Lin, Chen-Tan
Malone, Daniel C
Matlock, Daniel D
author_facet Trinkley, Katy E
Kahn, Michael G
Allen, Larry A
Haugen, Heather
Kroehl, Miranda E
Lin, Chen-Tan
Malone, Daniel C
Matlock, Daniel D
author_sort Trinkley, Katy E
collection PubMed
description INTRODUCTION: Consideration of patient preferences for guideline-directed medical therapies (GDMT) for heart failure with reduced ejection fraction (HFrEF) may help improve major gaps in prescribing and adherence. This study aimed to identify the range and relative priority of factors influencing patients’ decisions to take HFrEF medications. MATERIALS AND METHODS: This was a convergent mixed methods study of patients with HFrEF. Focus groups were conducted to identify a list of factors followed by individuals rating and ranking the influence of each factor on their decision to take a medication. Using thematic analysis, we summarized preferences into categories. RESULTS: Two focus groups with 13 participants reported 22 factors. Of the factors, “keeping you alive” was most commonly ranked in the top three (seven participants), followed by “communication and understanding” (six participants). Factors were summarized into six categories (listed in order of patient-reported influence): 1) demonstrated improvements in quality of life and longevity, 2) decreased risk of hospitalization, 3) opportunity for shared decision-making and trust in provider, 4) absence of adverse events, 5) affordability, and 6) convenience of taking and absence of interference with daily life. CONCLUSION: Patients prioritize treatment benefits and being informed more than risks, cost and inconvenience of taking HFrEF medications.
format Online
Article
Text
id pubmed-7667168
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-76671682020-11-16 Patient Treatment Preferences for Heart Failure Medications: A Mixed Methods Study Trinkley, Katy E Kahn, Michael G Allen, Larry A Haugen, Heather Kroehl, Miranda E Lin, Chen-Tan Malone, Daniel C Matlock, Daniel D Patient Prefer Adherence Original Research INTRODUCTION: Consideration of patient preferences for guideline-directed medical therapies (GDMT) for heart failure with reduced ejection fraction (HFrEF) may help improve major gaps in prescribing and adherence. This study aimed to identify the range and relative priority of factors influencing patients’ decisions to take HFrEF medications. MATERIALS AND METHODS: This was a convergent mixed methods study of patients with HFrEF. Focus groups were conducted to identify a list of factors followed by individuals rating and ranking the influence of each factor on their decision to take a medication. Using thematic analysis, we summarized preferences into categories. RESULTS: Two focus groups with 13 participants reported 22 factors. Of the factors, “keeping you alive” was most commonly ranked in the top three (seven participants), followed by “communication and understanding” (six participants). Factors were summarized into six categories (listed in order of patient-reported influence): 1) demonstrated improvements in quality of life and longevity, 2) decreased risk of hospitalization, 3) opportunity for shared decision-making and trust in provider, 4) absence of adverse events, 5) affordability, and 6) convenience of taking and absence of interference with daily life. CONCLUSION: Patients prioritize treatment benefits and being informed more than risks, cost and inconvenience of taking HFrEF medications. Dove 2020-11-10 /pmc/articles/PMC7667168/ /pubmed/33204073 http://dx.doi.org/10.2147/PPA.S276328 Text en © 2020 Trinkley et al. http://creativecommons.org/licenses/by-nc/3.0/ This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Original Research
Trinkley, Katy E
Kahn, Michael G
Allen, Larry A
Haugen, Heather
Kroehl, Miranda E
Lin, Chen-Tan
Malone, Daniel C
Matlock, Daniel D
Patient Treatment Preferences for Heart Failure Medications: A Mixed Methods Study
title Patient Treatment Preferences for Heart Failure Medications: A Mixed Methods Study
title_full Patient Treatment Preferences for Heart Failure Medications: A Mixed Methods Study
title_fullStr Patient Treatment Preferences for Heart Failure Medications: A Mixed Methods Study
title_full_unstemmed Patient Treatment Preferences for Heart Failure Medications: A Mixed Methods Study
title_short Patient Treatment Preferences for Heart Failure Medications: A Mixed Methods Study
title_sort patient treatment preferences for heart failure medications: a mixed methods study
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7667168/
https://www.ncbi.nlm.nih.gov/pubmed/33204073
http://dx.doi.org/10.2147/PPA.S276328
work_keys_str_mv AT trinkleykatye patienttreatmentpreferencesforheartfailuremedicationsamixedmethodsstudy
AT kahnmichaelg patienttreatmentpreferencesforheartfailuremedicationsamixedmethodsstudy
AT allenlarrya patienttreatmentpreferencesforheartfailuremedicationsamixedmethodsstudy
AT haugenheather patienttreatmentpreferencesforheartfailuremedicationsamixedmethodsstudy
AT kroehlmirandae patienttreatmentpreferencesforheartfailuremedicationsamixedmethodsstudy
AT linchentan patienttreatmentpreferencesforheartfailuremedicationsamixedmethodsstudy
AT malonedanielc patienttreatmentpreferencesforheartfailuremedicationsamixedmethodsstudy
AT matlockdanield patienttreatmentpreferencesforheartfailuremedicationsamixedmethodsstudy